- Home
- TVGN vs NSPR Comparison
TVGN vs NSPR Comparison
Compare TVGN & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- NSPR
- Stock Information
- Founded
- TVGN 2020
- NSPR 2005
- Country
- TVGN United States
- NSPR Israel
- Employees
- TVGN N/A
- NSPR N/A
- Industry
- TVGN Blank Checks
- NSPR Medical/Dental Instruments
- Sector
- TVGN Finance
- NSPR Health Care
- Exchange
- TVGN Nasdaq
- NSPR Nasdaq
- Market Cap
- TVGN 174.4M
- NSPR 63.0M
- IPO Year
- TVGN N/A
- NSPR N/A
- Fundamental
- Price
- TVGN $1.05
- NSPR $2.87
- Analyst Decision
- TVGN
- NSPR Strong Buy
- Analyst Count
- TVGN 0
- NSPR 2
- Target Price
- TVGN N/A
- NSPR $4.75
- AVG Volume (30 Days)
- TVGN 1.5M
- NSPR 33.6K
- Earning Date
- TVGN 02-20-2025
- NSPR 11-12-2024
- Dividend Yield
- TVGN N/A
- NSPR N/A
- EPS Growth
- TVGN N/A
- NSPR N/A
- EPS
- TVGN N/A
- NSPR N/A
- Revenue
- TVGN N/A
- NSPR $6,821,000.00
- Revenue This Year
- TVGN N/A
- NSPR $13.36
- Revenue Next Year
- TVGN N/A
- NSPR $49.64
- P/E Ratio
- TVGN N/A
- NSPR N/A
- Revenue Growth
- TVGN N/A
- NSPR 24.70
- 52 Week Low
- TVGN $0.26
- NSPR $1.81
- 52 Week High
- TVGN $21.09
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- TVGN 45.10
- NSPR 49.22
- Support Level
- TVGN $0.86
- NSPR $2.80
- Resistance Level
- TVGN $1.27
- NSPR $3.06
- Average True Range (ATR)
- TVGN 0.12
- NSPR 0.16
- MACD
- TVGN 0.02
- NSPR -0.03
- Stochastic Oscillator
- TVGN 46.73
- NSPR 17.50
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.